117 related articles for article (PubMed ID: 17523243)
1. 48-week study results show DRV's staying power.
Bernard EJ
IAPAC Mon; 2007 Jan; 13(1):10-1. PubMed ID: 17523243
[No Abstract] [Full Text] [Related]
2. Amping amprenavir with ritonavir.
TreatmentUpdate; 2001; 12(12):10. PubMed ID: 11570075
[No Abstract] [Full Text] [Related]
3. Impact of baseline protease genotype and phenotype on the response to darunavir outside clinical trials.
Poveda E; Vispo E; Pattery T; de Mendoza C; Villacian J; Soriano V
J Antimicrob Chemother; 2007 Dec; 60(6):1411-3. PubMed ID: 17911388
[No Abstract] [Full Text] [Related]
4. Drug interactions. Amprenavir with low-dose ritonavir.
TreatmentUpdate; 2006; 18(3):9-10. PubMed ID: 17211921
[No Abstract] [Full Text] [Related]
5. [Are all boosted protease inhibitors the same? Previously treated patients profit too from lopinavir/r].
MMW Fortschr Med; 2003 Dec; 145(50):61. PubMed ID: 14963981
[No Abstract] [Full Text] [Related]
6. Anti-HIV agents. Darunavir shows its strength.
TreatmentUpdate; 2006; 18(4):2-3. PubMed ID: 17205651
[No Abstract] [Full Text] [Related]
7. Darunavir/ritonavir monotherapy in clinical practice.
Parienti JJ
AIDS; 2011 Jan; 25(1):119. PubMed ID: 21119326
[No Abstract] [Full Text] [Related]
8. FDA clears HIV drug for patients with resistant virus.
AIDS Read; 2006 Aug; 16(8):392. PubMed ID: 16933372
[No Abstract] [Full Text] [Related]
9. Darunavir: promising initial results.
MacArthur RD
Lancet; 2007 Apr; 369(9568):1143-4. PubMed ID: 17416241
[No Abstract] [Full Text] [Related]
10. Resistance profiles observed in virological failures after 24 weeks of amprenavir/ritonavir containing regimen in protease inhibitor experienced patients.
Marcelin AG; Affolabi D; Lamotte C; Mohand HA; Delaugerre C; Wirden M; Voujon D; Bossi P; Ktorza N; Bricaire F; Costagliola D; Katlama C; Peytavin G; Calvez V
J Med Virol; 2004 Sep; 74(1):16-20. PubMed ID: 15258963
[TBL] [Abstract][Full Text] [Related]
11. Genotypic resistance analysis of the virological response to fosamprenavir-ritonavir in protease inhibitor-experienced patients in CONTEXT and TRIAD clinical trials.
Marcelin AG; Flandre P; Molina JM; Katlama C; Yeni P; Raffi F; Antoun Z; Ait-Khaled M; Calvez V
Antimicrob Agents Chemother; 2008 Dec; 52(12):4251-7. PubMed ID: 18852278
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics, safety and efficacy of darunavir/ritonavir in treatment-experienced children and adolescents.
Blanche S; Bologna R; Cahn P; Rugina S; Flynn P; Fortuny C; Vis P; Sekar V; van Baelen B; Dierynck I; Spinosa-Guzman S
AIDS; 2009 Sep; 23(15):2005-13. PubMed ID: 19724191
[TBL] [Abstract][Full Text] [Related]
13. Fosamprenavir (GW433908)/ritonavir in HIV-infected patients: efficacy and safety results from the Spanish Expanded Access Program.
Pérez-Elias MJ; Sánchez-Conde M; Soriano V; Mallolas J; Luque I; Rodríguez-Alcántara F;
Enferm Infecc Microbiol Clin; 2009 Jan; 27(1):28-32. PubMed ID: 19218000
[TBL] [Abstract][Full Text] [Related]
14. Lower dose of ritonavir approved for use with fosamprenavir.
Sax PE
AIDS Clin Care; 2007 Dec; 19(12):106. PubMed ID: 18399004
[No Abstract] [Full Text] [Related]
15. Anti-HIV agents. Darunavir shows its strength.
TreatmentUpdate; 2007; 19(5):2-4. PubMed ID: 17955613
[No Abstract] [Full Text] [Related]
16. Salvage therapy with amprenavir, lopinavir and ritonavir 200 mg/d or 400 mg/d in HIV-infected patients in virological failure.
Raguin G; Chêne G; Morand-Joubert L; Taburet AM; Droz C; Le Tiec C; Clavel F; Girard PM;
Antivir Ther; 2004 Aug; 9(4):615-25. PubMed ID: 15456093
[TBL] [Abstract][Full Text] [Related]
17. [After 3 years no resistance development. Protease inhibitor with staying power].
MMW Fortschr Med; 2002 Apr; 144 Suppl 1():56-7. PubMed ID: 12043076
[No Abstract] [Full Text] [Related]
18. Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis.
Mills AM; Nelson M; Jayaweera D; Ruxrungtham K; Cassetti I; Girard PM; Workman C; Dierynck I; Sekar V; Abeele CV; Lavreys L
AIDS; 2009 Aug; 23(13):1679-88. PubMed ID: 19487905
[TBL] [Abstract][Full Text] [Related]
19. Saquinavir plus ritonavir reduce viral load by 99.9 percent.
Vazquez E
Posit Aware; 1996; 7(6):8-9. PubMed ID: 11363983
[TBL] [Abstract][Full Text] [Related]
20. Analysis of drug resistance during HIV RNA viraemia in the MONET trial of darunavir/ritonavir monotherapy.
Pulido F; Arribas JR; Hill A; Van Delft Y; Moecklinghoff C
Antivir Ther; 2011; 16(1):59-65. PubMed ID: 21311109
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]